



27 **Abstract**

28 The genetic disease cystic fibrosis (CF) frequently leads to chronic lung infections by bacteria and fungi.  
29 We identified three individuals with CF with persistent lung infections dominated by *Clavispora (Candida)*  
30 *lusitaniae*. Whole genome sequencing analysis of multiple isolates from each infection found evidence for  
31 selection for mutants in the gene *MRS4* in all three distinct lung-associated populations. In each  
32 population, we found one or two unfixed, non-synonymous mutations in *MRS4* relative to the reference  
33 allele found in multiple environmental and clinical isolates including the type strain. Genetic and  
34 phenotypic analyses found that all evolved alleles led to loss of function of Mrs4, a mitochondrial iron  
35 transporter. RNA Seq analyses found that Mrs4 variants with decreased activity led to increased  
36 expression of genes involved in iron acquisition mechanisms in both low iron and replete iron conditions.  
37 Furthermore, surface iron reductase activity and intracellular iron was much higher in strains with Mrs4  
38 loss of function variants. Parallel studies found that a subpopulation of a CF-associated *Exophiala*  
39 *dermatiditis* infection also had a non-synonymous loss of function mutation in *MRS4*. Together, these  
40 data suggest that *MRS4* mutations may be beneficial during chronic CF lung infections in diverse fungi  
41 perhaps for the purposes of adaptation to an iron restricted environment with chronic infections.

## 42 Introduction

43 Evolution of pathogens in infections can lead to the rise of isolates with increased resistance to host  
44 defenses or drugs, improved fitness, or enhanced access to nutrients. An understanding of pathoadaptive  
45 mutations may improve therapies and treatments. The repeated rise of specific mutations in bacteria and  
46 fungi associated with chronic infections has been particularly well-documented in the context of lung  
47 infections in people with cystic fibrosis (CF). The genetic mutations that cause CF lead to chronic  
48 infections. Several studies have shown that nutritional immunity, mediated by innate immune effectors  
49 such as calprotectin which restrict access to metals, force microbes to employ diverse strategies to  
50 acquire essential nutrients such as iron and zinc (1-3).

51 Many of the mutations that repeatedly arise in CF-related bacterial and fungal pathogens are in  
52 regulators (e.g. *lasR* and *mucA* in *Pseudomonas aeruginosa*, *agr* in *Staphylococcus aureus*). Analysis of  
53 *Candida* CF isolates has found similar regulatory mutations. A study of *Candida albicans* CF infection  
54 identified six instances of loss-of-function (LOF) mutations in *NRG1*, which encodes a repressor of  
55 filamentation; *nrg1* LOF mutants are resistant to the suppression of filamentation by the frequently co-  
56 infecting bacterium *Pseudomonas aeruginosa* (4). We previously published that a single *Clavispora*  
57 (*Candida lusitanae*) infection, with no detectable co-infecting bacteria, had numerous activating and  
58 subsequent suppressing mutations in *MRR1* (5) that lead to heterogenous resistance to the antifungal  
59 fluconazole, the toxic metabolite methylglyoxal, and *P. aeruginosa* toxins. Longitudinal collections of  
60 *Aspergillus fumigatus* isolates from a single individual with CF showed acquired mutations that lead to  
61 HOG pathway hyperactivation and improved fitness in the presence of oxidative and osmotic stress (6).

62 In this work, we describe a locus in *C. lusitanae* (7) that was independently mutated in three separate  
63 subjects with CF. *C. lusitanae*, a haploid member of the CTG clade within the Saccharomycetaceae  
64 family, is known to readily develop Amphotericin B resistance (8) and can develop resistance to  
65 caspofungin and azoles (9, 10). *C. lusitanae* has been reported in association with plant and food  
66 products, and is a less commonly found to be an abundant member of microbiome communities. Notably,  
67 *C. lusitanae* is closely related to *Candida auris* which is also known for the repeated development of  
68 multi-drug resistance, and is a critical threat on the WHO priority pathogens list (11, 12).

69 *C. lusitaniae* evolution in the CF lung may provide an opportunity to study fungal adaptation to host  
70 environments. We found non-synonymous mutations in *MRS4* arose independently in three different CF  
71 lung infections. Mrs4 is a high affinity inner mitochondrial membrane iron transporter that brings iron into  
72 the inner lumen. In other fungi, Mrs4-mediated iron transport is necessary for robust growth in low iron  
73 environments, resistance to Cons and menadione, and its function supports the synthesis of iron-sulfur  
74 clusters for incorporation into diverse enzymes and regulators (13-18). Previous studies found that *MRS4*  
75 deletion significantly reduces virulence of *C. albicans* in a murine model for systemic candidiasis (19). We  
76 found that each of the Mrs4 variants had decreased function. RNA seq analysis of isolates with different  
77 *MRS4* alleles in iron replete and iron restricted conditions demonstrated that Mrs4 LOF led to significant  
78 increases in expression of multiple iron uptake methods. Furthermore, strains with *MRS4* LOF alleles  
79 demonstrated increased accumulation of intracellular iron. A LOF mutation in *MRS4* was also found in CF  
80 infection isolates of *Exophiala dermatitidis*. Taken together, these data highlight that in two distinct  
81 environmental fungi, chronic infection leads to the selection for Mrs4 variants with decreased function and  
82 an increased capacity for iron uptake. Future studies will determine if these host-adapted strains have  
83 new vulnerabilities that can be exploited therapeutically.

84

85

## 86 Results

### 87 ***MRS4* mutations are found in *C. lusitaniae* from CF lung infections**

88 Analysis of the microbiota in bronchoalveolar lavage (BAL) fluids collected at Dartmouth Health  
89 found three subjects CF with lung infections dominated by *C. lusitaniae* ((7) and in a manuscript in  
90 preparation). We sequenced the genomes of 12-20 isolates from each population (see Methods section  
91 for Accession numbers). To identify mutations that likely arose during infection, non-synonymous single  
92 nucleotide polymorphisms (SNPs) that were not fixed within the population from each individual were  
93 determined (**Table S1**). Nineteen genes had two alleles with non-synonymous differences in more than  
94 one population, defined as isolates from a single subject at a single time point, and only one gene had  
95 alleles with non-synonymous differences within in all three populations: *CLUG\_02526* (**Figure 1A**).  
96 *CLUG\_02526* encodes an amino acid sequence with 71% identity with *C. albicans* SC5314 Mrs4 (19),  
97 and 51% with *Saccharomyces cerevisiae* S288C Mrs3 and Mrs4 (**Figure S1**). Mrs4 functions as high  
98 affinity mitochondrial iron importers in both species (16, 20). Due to the high percent sequence identity  
99 and our phenotypic characterization of *CLUG\_02526* deletion mutants (described below), we will  
100 heretofore refer to *CLUG\_02526* as *MRS4*.

101 To compare the *MRS4* sequences from CF *C. lusitaniae* isolates to *MRS4* sequences to a  
102 broader collection of *C. lusitaniae* strains, we also analyzed *MRS4* in ten *C. lusitaniae* isolates from  
103 diverse clinical and environmental sources. We found that the predicted Mrs4 amino acid sequences  
104 were identical and the genes differed by only a small number of synonymous SNPS that varied among  
105 alleles (**Figure S2**). The conserved Mrs4 amino acid sequence will be referred to as the “reference” or  
106 Mrs4<sup>REF</sup> sequence. Isolates with *MRS4* alleles that encoded the Mrs4<sup>REF</sup> sequence were found in both  
107 Subject A and Subject C (**Figure 1B**). In addition to the reference allele, Subject A and Subject C  
108 populations each had isolates with mutant alleles that differed by single non-synonymous SNPs, and  
109 encoded *MRS4*<sup>A235V</sup> and *MRS4*<sup>G138V</sup>, respectively (**Figure 1B**). Subject B isolates carried one of two  
110 mutant alleles that encoded *MRS4*<sup>A147D</sup> and *MRS4*<sup>Q254\*</sup> (**Figure 1B**), suggesting that two independent  
111 *MRS4* mutant lineages arose within that population. The Mrs4 substitutions or terminations occurred in  
112 predicted transmembrane alpha helices of the protein (**Figure 1C**) and occurred at residues that were  
113 conserved across diverse species (**Figure S1**). Each *MRS4* mutation found in the CF *C. lusitaniae*

114 isolates had a high likelihood of affecting function based on the SuSPECT analysis method which  
115 estimates the probability for single amino acid variants to impact phenotype (**Figure S3**) (21).

116

117 **Spatial and longitudinal analyses show that *MRS4* alleles may have arisen independently in**  
118 **different regions of the lung and that *Mrs4* LOF isolates persisted over time and across**  
119 **compartment.**

120 Using whole genome sequence data for pools of 75-96 isolates from the upper and lower lobes of  
121 the right lung of Subject A and the upper, middle and lower lobes of the left lung of Subject B, we  
122 determined the fraction of reads that encoded the *MRS4* SNPs described above within each pool. For the  
123 pooled isolates of the upper lobe of Subject A, the reads contained only the *MRS4*<sup>REF</sup> allele, while ~43%  
124 of sequenced population from the lower lobe had the *MRS4*<sup>A235V</sup> allele (**Figure 1D**). Both alleles were  
125 detectable in the upper, middle, and lower lobe isolate pools of Subject B, with the *MRS4*<sup>A147D</sup> allele  
126 present at a higher percentage in the upper and lower lobe (~83 and 89%, respectively), while *MRS4*<sup>Q254\*</sup>  
127 was found in ~93% of reads in the middle lobe. Sequence analysis of four sputum isolates from a sample  
128 donated by subject A, collected ~1 year after the BAL isolates were recovered, found two isolates with  
129 *MRS4*<sup>REF</sup> and two isolates with *MRS4*<sup>A235V</sup> suggesting that the *MRS4* variant-containing isolates persisted  
130 over time. Similarly, we obtained 6 respiratory sputum and stool isolates from Subject B more than one  
131 year after the initial isolation and amplified and sequenced the *MRS4* allele. We found that they all  
132 contained the *MRS4*<sup>A147D</sup> allele. These longitudinal isolates indicate that the *MRS4* mutations persisted  
133 over time and possibly in multiple compartments, and thus were not transiently present at the time of  
134 isolation.

135

136 ***MRS4* variants confer LOF phenotypes**

137 In other fungi, the deletion of *MRS4* impairs growth in low iron media or the presence of an iron chelator  
138 (17, 20, 22). To determine the activity of *Mrs4* variants in the *C. lusitaniae* CF isolates, we first constructed  
139 an *mrs4*Δ derivative of Subject B isolate B\_L01, which had an *MRS4*<sup>Q254\*</sup> allele, then complemented back  
140 either the native B\_L01 *MRS4*<sup>Q254\*</sup> allele or *MRS4*<sup>REF</sup> at the native locus (**Figure 2A**). We chose the *MRS4*  
141 allele from strain ATCC 42720 as the source of the *MRS4*<sup>REF</sup> sequence. We observed that all four isogenic

142 strains (B\_L01 parental isolate, the *mrs4* $\Delta$  mutant, and the *mrs4* $\Delta$  mutant complemented with *MRS4*<sup>REF</sup> or  
143 *MRS4*<sup>Q254\*</sup>) reached similar yields in YPD (**Figure 2B**). Yields were reduced in YPD amended with a high-  
144 affinity ferrous iron chelator bathophenanthroline disulfonate (BPS), and we observed differences  
145 dependent on *MRS4* allele (**Figure 2B**). Deletion of *mrs4* in the B\_L01 background reduced final yield.  
146 Complementation with the *MRS4*<sup>REF</sup> allele restored growth to a significantly greater degree than the parent  
147 strain, or to the B\_L01 *mrs4* $\Delta$  complemented with the native allele. These results indicate that the truncated  
148 variant has decreased function relative to the reference allele, but that the truncated variant may retain  
149 some function.

150 Deletion mutants lacking *MRS4* in *S. cerevisiae* and *C. albicans* have altered metal sensitivities  
151 such that mutants are more resistant to cobalt and more sensitive to cadmium when compared to their  
152 *Mrs4*+ counterparts (17, 20) due to activation of transcription factors such as Aft1 in *S. cerevisiae* (15).  
153 We found that cadmium and cobalt affected the growth of *C. lusitaniae* in an *MRS4* allele dependent  
154 manner. The B\_L01 *mrs4* $\Delta$  derivative and the *mrs4* $\Delta$  complemented with the allele encoding *Mrs4*<sup>Q254\*</sup>  
155 were more resistant to cobalt than the *mrs4* $\Delta$  mutant complemented with *MRS4*<sup>REF</sup> (**Figure 2C**).  
156 Conversely, the *mrs4* $\Delta$  strain complemented with the *Mrs4*<sup>REF</sup> variant was more resistant to cadmium than  
157 the *mrs4* $\Delta$  mutant or the mutant complemented with *Mrs4*<sup>Q254\*</sup>. Together, these data further suggest that  
158 the *Mrs4*<sup>Q254\*</sup> variant is less functional than the reference allele.

159 To characterize the levels of function for the other three *Mrs4* variants found in the CF clinical *C.*  
160 *lusitaniae* isolates, we created *mrs4* $\Delta$  derivatives of isolates A\_U05 (*MRS4*<sup>A235V</sup>), B\_L04 (*MRS4*<sup>A147D</sup>), and  
161 C\_M06 (*MRS4*<sup>G138V</sup>) which were then complemented with the *MRS4*<sup>REF</sup> allele. In each case,  
162 complementation with the functional *MRS4*<sup>REF</sup> allele made cells more sensitive to cobalt (**Figure 3A**) as  
163 was the case for strain B\_L01. Similarly, replacement of *MRS4* with the *MRS4*<sup>REF</sup> allele increased  
164 cadmium sensitivity in B\_L04 (*MRS4*<sup>A147D</sup>), and C\_M06 (*MRS4*<sup>G138V</sup>) (**Figure 3B**). Unexpectedly, the  
165 A\_U05 (*MRS4*<sup>A235V</sup>) isolate had greater resistance to cadmium than the same background with the  
166 *MRS4*<sup>REF</sup> allele, perhaps due to other genetic differences. When we expressed *MRS4*<sup>A235V</sup> in B\_L01  
167 *mrs4* $\Delta$ , the resultant strain was more sensitive to cadmium than the isogenic strain with *MRS4*<sup>REF</sup>  
168 supporting the conclusion that the *Mrs4*<sup>A235V</sup> variant had low or no activity (**Figure S4**). We also made an  
169 *mrs4* $\Delta$  mutation in an outgroup *C. lusitaniae* strain RSY284 (DH2383) (23) with a native *MRS4*<sup>REF</sup> allele,

170 and confirmed that the mutant had the expected resistance to cobalt and sensitivity to cadmium (**Figure**  
171 **S5A**). Together, these data suggest that LOF mutations in *MRS4* arose four independent times across  
172 three chronic CF infections indicating possible selection for phenotypes associated with loss of Mrs4  
173 function.

174

175 **Characterization of *MRS4* growth phenotypes.** Mitochondrial metabolism is highly dependent  
176 on the availability of metals such as iron. To assess whether the *MRS4* loss-of-function alleles affected  
177 mitochondrial activity, we examined the growth of isogenic strains with either *MRS4*<sup>REF</sup> or Mrs4<sup>Q254\*</sup> in  
178 medium with either glucose (which can be fermented) or glycerol as the major carbon source. In both  
179 yeast extract peptone medium or yeast nitrogen base media with 2% glucose, there was a slightly faster  
180 growth for the strain with Mrs4<sup>REF</sup> compared to the *mrs4* null mutant or strains with Mrs4<sup>Q254\*</sup> but the  
181 differences were not significant (**Figure 4A and C**). Similar results were obtained when grown in medium  
182 with glycerol as the dominant or sole carbon source (**Figure 4B and D**). These results suggested that  
183 there was no major defect in respiratory metabolism.

184 As a more sensitive indicator of changes in levels of respiration and fermentation, we quantified  
185 glucose consumption relative to fermentation product production by HPLC. Analysis of supernatants from  
186 cultures of the *mrs4*Δ + *MRS4*<sup>REF</sup> strain grown in medium with glucose as the sole carbon source found  
187 that the dominant fermentation product was acetate followed by ethanol; glycerol was not detected. Under  
188 the same conditions, *C. albicans* strain SC5314 produced mainly ethanol with low levels of acetate and  
189 glycerol. Normalized to moles of carbon, *C. lusitaniae* converted more than twice as much glucose to  
190 fermentation products than *C. albicans* (**Table S2**). When the mass balance of glucose consumed and  
191 fermentation products made for *C. lusitaniae mrs4*Δ + *MRS4*<sup>Q254\*</sup> and *mrs4*Δ + *MRS4*<sup>REF</sup> were compared,  
192 we found no significant differences suggesting comparable levels of respiration and fermentation (**Table**  
193 **S2**). We also constructed a *C. albicans mrs4*Δ/Δ homozygous mutant and found no significant difference  
194 in fraction of carbon used for fermentation when the SC5314 wild type was compared to the *mrs4*Δ/Δ  
195 homozygous mutant (**Table S2**).

196 To further assess metabolic differences associated with Mrs4 LOF, we analyzed growth of B\_L01  
197 parent and *mrs4*Δ::*MRS4*<sup>REF</sup> on different sole carbon sources using the Biolog™ carbon utilization



198 phenotype microarray plates. We inoculated equal concentrations of each strain in YNB minimal medium  
199 and observed growth over the course of 48 h. Across the 192 carbon sources tested, there were no  
200 differences in growth that were confirmed in secondary analysis (**Supplementary dataset 1**). Analysis of  
201 B\_L01 parent and B\_L01::*MRS4*<sup>REF</sup> did not show any differences in minimal inhibitory concentrations for  
202 commonly used antifungals including fluconazole and amphotericin B (data not shown). Consistent with  
203 published studies in *Cryptococcus neoformans* (24), in *C. lusitaniae* DH2383 and B\_L01, functional Mrs4  
204 was necessary for full H<sub>2</sub>O<sub>2</sub> resistance (**Figure S5**).

205

### 206 ***MRS4* LOF impacts expression of iron homeostasis regulators and metal storage**

207 To gain insight into how Mrs4 LOF affected *C. lusitaniae*, we performed a transcriptomics  
208 analysis of B\_L01 *mrs*Δ with *MRS4*<sup>REF</sup> and *MRS4*<sup>Q254\*</sup>. Because cells with defective Mrs4 (e.g. *MRS4*<sup>Q254\*</sup>)  
209 showed reduced growth on medium with chelator (**Figure 2B**), we performed an RNA-seq analysis of  
210 cells from mid-exponential phase cultures growing in YPD and parallel cultures that received a 1 h  
211 exposure to the iron chelator BPS (**Figure 5A** for experimental scheme). The short exposure to BPS was  
212 used to limit the pleiotropic effects associated with growth differences. Comparison of the strains with  
213 *MRS4*<sup>REF</sup> without or with exposure to iron chelator found eleven genes that had a fold difference greater  
214 than log<sub>2</sub> 1 and a false discovery corrected p-value less than 0.05 (**Figure 5B** and **Supplementary**  
215 **dataset S2**). Among the genes that were differentially expressed were four cell surface high affinity ferric  
216 iron uptake genes (*FTR1*, *FRE9*, *FRE10*, and *FET31*) and genes that encode regulators involved in iron  
217 utilization *SFU1* and *HAP43* (**Figure 5B**) which are known to be transcriptionally regulated in response to  
218 iron limitation response in other *Candida* species (25, 26).

219 Comparison of the transcriptomes of B\_L01 *mrs*Δ+*MRS4*<sup>REF</sup> to B\_L01 *mrs*Δ+*MRS4*<sup>Q254\*</sup> after  
220 chelator exposure found that the same ferric reductases that were induced upon exposure to chelator in  
221 the Mrs4<sup>REF</sup> strain were higher in cells with Mrs4<sup>Q254\*</sup> (**Figure 5C**). We again found differential expression  
222 of the *SFU1* and *HAP43* regulators, and also found greater fold induction of the gene encoding pro-iron  
223 acquisition transcription factor *SEF1* in the *mrs*Δ+*MRS4*<sup>Q254\*</sup> relative to *mrs*Δ+*MRS4*<sup>REF</sup> with chelator. In  
224 addition, we found differential expression of putative orthologs of iron uptake genes (*SIT1*, *CSA1*) and  
225 other metal transporters (*CCC1*, *CCC2*) (27) when Mrs4 function was low. *MRS4* transcript levels were

226  $\log_2$  1.7 fold higher in the *mrs4 $\Delta$ +MRS4<sup>Q254\*</sup>* strain, and the *MRS4*-adjacent gene *GOR1*, predicted to  
227 encode a glyoxylate reductase, was also significantly higher in the *Mrs4<sup>Q254\*</sup>* bearing strain.

228 We also compared transcriptomes of *mrs $\Delta$ +MRS4<sup>REF</sup>* and *mrs4 $\Delta$ +MRS4<sup>Q254\*</sup>* in control conditions  
229 without chelator. Thirty-seven genes were differentially expressed across the two strains in the presence  
230 of chelator (**Figure 5C**), and 27 of them were still differentially expressed in its absence (**Figure 5D**).  
231 Ferric reductase encoding genes and their regulators (e.g. *HAP43*) were again differentially expressed,  
232 and the fold difference between strains was higher than in the chelator condition (**Figure 5C** and **D**). An  
233 independent experiment, using qRT-PCR analysis of RNA from *mrs $\Delta$ +MRS4<sup>REF</sup>* and *mrs4 $\Delta$ +MRS4<sup>Q254\*</sup>*  
234 also found transcript levels of *HAP43* and *FRT1* to be significantly higher in both iron replete and iron  
235 chelated conditions (**Figure S6**). We also observed that *mrs $\Delta$ +MRS4<sup>REF</sup>* had ~4.5 fold higher levels of  
236 *INO1*, the ortholog of inositol-3-phosphate synthase, than *mrs4 $\Delta$ +MRS4<sup>Q254\*</sup>* in YPD (**Figure 5D**).

237

### 238 **Loss of Mrs4 function leads to higher surface ferric reductase activity**

239 We sought to determine if the higher levels of in transcripts encoding cell surface ferric  
240 reductases in *MRS4<sup>Q254\*</sup>* strains, even in iron-replete conditions, translated into higher levels of iron  
241 acquisition activity. To do so, we utilized tetrazolium chloride (TTC), a substrate for ferric reductases (28).  
242 To avoid complications associated with growth inhibition by TTC, we grew colonies on YNB-glycerol agar  
243 for 24 h, then overlaid with molten 1% agar containing TTC (**Figure 6A**). Upon TTC reduction by ferric  
244 reductases, an insoluble red pigment forms. After ten minutes, there was a strong red coloration  
245 associated with colonies formed by *MRS4<sup>Q254\*</sup>* and the *mrs4 $\Delta$*  strains, but not the *MRS4<sup>REF</sup>* strain (**Figure**  
246 **6A**). The TTC reduction phenotype was abrogated by the addition of excess ferric iron in the agar overlay  
247 (**Figure 6A**). These data suggest greater ferric reductase activity on the cell surface when Mrs4 activity is  
248 low. Similar results though to a lesser degree were observed on YPD medium (**Figure 6B**).

249 Previously studies showed that decreased mitochondrial iron levels induced the activity of *C.*  
250 *lusitaniae* transcription factors by modulating cytosolic Fe-S-containing regulators. We predicted that  
251 Hap43 (within the Hap43-Sfu1-Sef1 transcription factor network) was part of this response that led to  
252 increased expression of iron uptake genes. Thus, we analyzed a *hap43 $\Delta$*  mutant in the B\_L01  
253 background with the defective *Mrs4<sup>Q254\*</sup>* variant, and found that Hap43 indeed contributed to the

254 increased levels of iron reductase activity created by Mrs4 LOF (**Figure 6B**). We also found that surface  
255 ferric reductase activity was higher in the *mrs4*Δ strains if *C. lusitaniae* strain 2383 and *C. albicans*  
256 SC5314 *mrs4*Δ/Δ. In *C. albicans*, both copies of *MRS4* to be deleted for manifestation of the increased  
257 surface ferric reductase phenotype.

258

### 259 **Mrs4 LOF leads to the accumulation of intracellular iron**

260 To evaluate the consequences of differential expression of iron acquisition genes in strains with  
261 and without Mrs4 function, we analyzed the concentrations of cellular iron by ICP-MS. In iron replete YPD  
262 medium, the strain *mrs4*Δ+ *MRS4*<sup>Q254\*</sup> had significantly higher levels of intracellular iron than  
263 *mrs4*Δ::*MRS4*<sup>REF</sup> (**Figure 6D**). In cells subjected to chelator treatment for 1 h prior to harvest, intracellular  
264 iron was lower than in the untreated cells, but still significantly higher in the *mrs4*Δ::*MRS4*<sup>Q254\*</sup> strain.  
265 These data suggest that the observed increase in iron acquisition gene transcripts was concomitant with  
266 higher intracellular iron which may be advantageous *in vivo* and may explain the repeated LOF of Mrs4 in  
267 clinical *C. lusitaniae* populations.

268

### 269 **MRS4 mutations in other fungi of clinical interest**

270 In light of variation in *MRS4* in three different *C. lusitaniae* populations, we investigated the  
271 consequences of two other naturally-occurring *MRS4* allelic variations that we observed in other species.  
272 First, we assessed the activity of Mrs4 variants in *Candida auris*, a fungus that emerged within the past  
273 forty years (29) and is closely related to *C. lusitaniae*. Multidrug resistant strains that caused localized  
274 outbreaks emerged independently within genetically distinct clades. Analysis of *Candida auris* *MRS4*  
275 alleles within and between clades, available from published sequences (30), found that the encoded Mrs4  
276 sequences were identical, with one exception. Clade I strains differed from strains in the other clades in  
277 that the *MRS4* allele encoded Mrs4<sup>31V</sup> while others encoded Mrs4<sup>31A</sup>. This difference was confirmed by  
278 Sanger sequencing. To assess the activity of these two Mrs4 variants, we expressed them in a *C.*  
279 *lusitaniae* *mrs4*Δ mutant. Both *C. auris* Mrs4<sup>31A</sup> and Mrs4<sup>31V</sup> alleles were able to complement *mrs4*Δ for  
280 growth with iron chelator and cadmium sensitivity to a similar extent as the functional *C. lusitaniae*  
281 Mrs4<sup>REF</sup> protein (**Figure S7**), indicating that both alleles were functional.

282           The second analysis of Mrs4 variants was in the black yeast *Exophiala dermatitidis*. We had  
283 previously identified a CF infection predominated by *E. dermatitidis*. We performed whole genome  
284 sequencing of twenty-three isolates and found a subpopulation of isolates with a non-synonymous SNP in  
285 the *MRS4* (**Figure 7A**) (31). Subsequent Sanger sequencing confirmed that seven of the twenty three  
286 isolates carried an *MRS4* ortholog with a sequence identical to the *E. dermatitidis* type strain, NIH8656  
287 (referred to here as encoding Mrs4<sup>40E-REF</sup>). The other sixteen sequenced isolates had a variant *MRS4* with  
288 an E40G substitution. To characterize the *MRS4* alleles in these *E. dermatitidis* isolates, both were  
289 synthesized and heterologously expressed in *C. lusitanae* *mrs4*Δ and assessed for function relative to  
290 the *C. lusitanae* *MRS4* alleles. The *E. dermatitidis* alleles (*EdMRS4*<sup>40E-REF</sup> and *EdMRS4*<sup>40G</sup>) were codon  
291 optimized for *Candida* spp. and the spliced introns were removed. The *EdMRS4* alleles were introduced  
292 at the native *MRS4* site and expressed under the control of the *C. lusitanae* *MRS4* promoter.

293           Complementation of the *mrs4*Δ strain with Mrs4<sup>40E-REF</sup> fully complemented the *mrs4*Δ mutant to  
294 the levels of *C. lusitanae* *MRS4*<sup>REF</sup>. In the presence of the BPS iron chelator, the *mrs4*Δ strain with the *E.*  
295 *dermatitidis* Mrs4<sup>40G</sup> variant had significantly reduced growth compared to a strain with *E. dermatitidis*  
296 Mrs4<sup>40E</sup>, which fully restored the Mrs4 function to levels observed for the *C. lusitanae* reference gene  
297 (**Figure 7B**). This indicates that a Mrs4 LOF mutation also arose in a population of *E. dermatitidis* during  
298 a CF lung infection. The repeated occurrence of *MRS4* mutations in fungal CF infections strongly  
299 suggests a selective benefit for *MRS4* LOF mutations in the CF lung.

300

## 301 **Discussion**

302           In this work, we showed the repeated loss of Mrs4 activity across two fungal species, *C. lusitanae*  
303 and *E. dermatitidis*, in the context of chronic CF lung infections. Each acquired non-synonymous  
304 mutations that resulted in reduced or loss of Mrs4 function, which led to defects in iron import into the  
305 mitochondrial inner lumen and increased expression and activity of iron acquiring pathways. The  
306 selection for *MRS4* LOF mutations in chronic lung infection may inform future studies on the mechanism  
307 of fungal persistence within the host and resistance to therapeutic strategies. The emergence of Mrs4  
308 LOF in two diverged species of Ascomycota, both environmental fungi which colonized chronic CF lung  
309 infections, highlights the possibility that mutations in *MRS4* may be important for the shift to commensal

310 colonizing yeast. Work by Kim et al. (4) found *C. albicans* *NRG1* LOF mutations in isolates from different  
311 individuals with CF suggesting that inactivating mutations in this locus increased fitness. Interestingly,  
312 mutants in *Nrg1* have increased expression of iron uptake genes (32).

313 In other species, mutation of *Mrs4* leads impairs the mitochondrial synthesis of Fe-S clusters, and  
314 Fe-S cluster levels modulate the iron starvation response through their insertion into specific transcription  
315 regulators in ways that modulate activity of the iron response network that includes Hap43, Sef1, Sfu1  
316 (14, 15, 33). Thus, *Mrs4* mutation broadly promotes the induction of iron acquisition pathways even in iron  
317 replete conditions as we observed (**Figure 4D**). Thus, *MRS4* mutations may be a key mechanism for a  
318 simultaneous increase in activity of multiple regulators. Because inactivating mutations in genes encoding  
319 Sfu1, the transcriptional repressor of iron uptake or Yfh1, the iron-sulfur exporter, would only activate a  
320 subset of pathways or have other pleiotropic effects on the cell. Unlike LOF or gain-of-function mutations  
321 in iron regulators themselves, the *MRS4* mutation did not result in constitutive derepression of the  
322 complete iron uptake regulon, as we observed a reduction in expression level of genes involved in the low  
323 iron response in iron-replete media and this level of regulation may be beneficial in preventing the  
324 accumulation of toxic concentrations of iron and other metals.

325 In chronic infections, such as those in the CF lung, the host restricts the availability of essential  
326 nutrients such as iron via nutritional immunity (34). Host proteins such as lactoferrin, transferrin, and  
327 calprotectin sequester iron, making it less accessible to pathogens. Enhanced expression of siderophore  
328 acquisition pathways (e.g. SIT1) and surface ferric reductases (e.g. those encoded by *CLUG\_02348* and  
329 *CLUG\_04344*) by *C. lusitaniae* likely provides a significant advantage in acquiring iron from iron  
330 sequestering molecules. The increased accumulation of cellular iron may aid cells during fluctuations in  
331 iron availability, such as what might occur in the lung environment that experiences cycles of increased  
332 inflammation associated with disease exacerbations and inflammation resolution. *Candida* species also  
333 have mechanisms to acquire iron from heme which represents approximately 80% of iron within the body.  
334 In chronic bacterial infections, evidence suggests that heme utilization is active (35, 36). *Candida* species  
335 employ a three-factor system for the acquisition of heme, using the secreted factor Csa2 to bind and ferry  
336 heme to the cell surface, where it is brought into the cell by Pga7 and Rbt5. Heme acquisition pathways  
337 (*CLUG\_4093*, *CLUG\_4096*, and *CLUG\_4097*) were at significantly higher levels in *MRS4*<sup>Q254\*</sup> than in

338 *MRS4<sup>REF</sup>* (Figure 5C and D) in both control and iron chelated conditions. A role for Mrs4 in chronic  
339 conditions is an interesting contrast to the importance of Mrs4 function in systemic fungal infections and it  
340 is interesting to consider different iron demands and sources in different types of infections (19).

341         Decreased Mrs4 activity may allow cells to accumulate high levels of iron without jeopardizing  
342 mitochondrial function. Iron is highly regulated by all cells due to its reactive properties. *MRS4* mutation  
343 may not only enhance iron uptake, but also limit iron concentrations in mitochondria which protects  
344 mitochondria from damage. Reduced iron uptake by mitochondria may be key for the accumulation of  
345 total cellular iron.

346         One unique feature of the three CF *C. lusitaniae* infections was that there were no detectable  
347 bacterial pathogens as the time of the BAL sample collection. When other *Candida* species are detected  
348 in CF, the fungi are usually part of a mixed bacterial-fungal infection. The reason for these intriguing  
349 differences is not known and a current area of study. Here, we showed that when compared to *C.*  
350 *albicans* SC5314, *C. lusitaniae* produced significantly less ethanol and more acetate as fermentation  
351 products. Ethanol stimulates biofilm formation and virulence factor production in CF bacterial pathogens  
352 (37, 38), and thus metabolic differences between fungi may be a differentiating factor. Mutations in *MRS4*  
353 may also be an important factor in competing with other microbes for iron. Lastly, *C. albicans* and *C.*  
354 *lusitaniae* differ in the degree to which they stimulate macrophages and thus differences in immune  
355 response may play an important role. Future studies will determine how different species persist in  
356 chronic infections, the roles specific mutations that are repeatedly under selection, and whether there are  
357 common themes across different pathogens. Chronic infection by microbes that are not also human  
358 commensals, such as *C. lusitaniae* and *E. dermatiditis*, provide an opportunity to study initial adaptations  
359 to the host environment and factors that are most critical for survival and persistence.

360

## 361 **Materials and Methods**

362

### 363 **Clinical isolate collection from respiratory samples.**

364         Clinical isolates were acquired from sputum and bronchoalveolar lavage (BAL) fluid samples that  
365 were plated on YPD (1% yeast extract, 2% peptone, 2% glucose, 1.5% agar) containing gentamycin,

366 blood agar or CHROMagar Candida media then restructured on YPD to obtain single isolates which were  
367 then saved in 25% glycerol. *C. lusitaniae* clinical isolates were obtained in accordance with the study  
368 protocol approved by Dartmouth Health Institutional Review Board (#22781) using methods described in  
369 (5).

370

### 371 **DNA isolation, genome sequence analysis and variant calling.**

372 Genomic DNA was extracted from cultures grown in YPD (2% peptone, 1% yeast extract, and 2% glucose)  
373 for ~16 hours; extractions were performed using the MasterPure yeast DNA purification kit (Epicentre). Genomic  
374 libraries, for single and pooled isolate DNA, were prepared using the KAPA HyperPrep Kit and sequenced using  
375 paired-end 150 bp reads on the Illumina NextSeq500 platform, to a depth of 100-150x coverage per sample as  
376 described in Demers *et al.* (5). The pipeline for genome analyses is available in a github repository  
377 ([https://github.com/stajichlab/PopGenomics\\_Clusitaniae](https://github.com/stajichlab/PopGenomics_Clusitaniae); doi: 10.5281/zenodo. 7800401). The short read  
378 sequences were aligned to a modified version (5) of the *Candida lusitaniae* ATCC 42720 genome (39). The ATCC  
379 42720 genome was altered to remove mitochondrial fragments inserted into the nuclear assembly and the  
380 mitochondrial contig (Supercontig\_9) was replaced by a complete mitochondrial genome from strain *C. lusitaniae*  
381 CBS 6936 (NC\_022161.1). The following regions were masked out due to unusually high coverage and likely  
382 mitochondrial origin: (Supercontig\_1.2:1869020-90 1869184,1664421-1664580; Supercontig\_1.3:1076192-  
383 1076578,1324802- 1324956,1353096-1353260; Supercontig\_1.6:126390-126604; Supercontig\_1.8:29199-92  
384 29370). Alignments were made using bwa (0.7.17-r1188) (40) and stored as a sorted, aligned read CRAM file with  
385 Picard (2.14.1, <http://broadinstitute.github.io/picard/>) to assign read groups and mark duplicate reads (script  
386 01\_align.sh). CRAM files were processed to realign reads using GATK's RealignerTargetCreator v4.1.8.1 and  
387 IndelRealigner following best practices of GATK (41). Each realigned CRAM file was processed with GATK's  
388 HaplotypeCaller (script 02\_call\_gvcf.sh) followed by joint calling of variants on each Chromosome using GATK's  
389 GenotypeGVCF method script 03\_jointGVCF\_call\_slice.sh). This step also removed low quality variant positions: low  
390 quality SNPs were filtered based on mapping quality (score <40), quality by depth (<2 reads), Strand Odds Ratio  
391 (SQR>4.0), Fisher Strand Bias (>200), and Read Position Rank Sum Test (<-20). These files were combined to produce  
392 a single variant call format (VCF) file of the identified variants to produce list of high quality polymorphisms (script



393 04\_combine\_vcf.sh). The quality filtered VCF file containing only variants among the clinical isolates was categorized  
394 by SnpEff (5.1) (42) and the ATCC 42720 gene annotation. Genome assemblies of the strains was performed  
395 with SPAdes (v3.12.0) (42) after trimming and adaptor cleanup of the reads was performed with  
396 AdaptorRemoval (v2.0) (43) and quality trimming with sickle (v1.33) (44). *De novo* assemblies were further  
397 screened for vector contamination with vecscreen step of AAFTF v0.3.1  
398 (<https://github.com/stajichlab/AAFTF>) (doi: [10.5281/zenodo.1620526](https://doi.org/10.5281/zenodo.1620526)). The metadata for the strains  
399 corresponding to the genome sequences for isolates from these three subjects will be described in a  
400 Microbial Resource Announcement submitted prior to publication of this work. The raw sequence reads for  
401 whole genome sequencing of Subject A, B, and C isolates have been deposited into NCBI sequence read  
402 archive under BioProject # PRJNA948351. Details for the isolates and isolate pools from different regions  
403 of the lung for Subject A are described in (5). For the analysis of *MRS4* sequences from environmental *C.*  
404 *lusitaniae* strains (**Table S3**) and from clinical isolates obtained from subsequently obtained sputum or stool  
405 sample was performed by amplifying *MRS4* using primers DRM031 and DRM032 and sequenced using  
406 these primers along with primer ED157 which binds within the *MRS4* sequence (see **Table S4** for primer  
407 sequences).

408

#### 409 **Strains and mutant construction.**

410 Fungal strains and plasmids used in this study are listed in **Table S3**. Fungi were maintained on YPD  
411 medium. CRISPR-Cas9 knockout of *MRS4* from clinical isolates was performed using previously  
412 described methods (45). For complementation of the reference *MRS4* allele, 5' UTR and coding region  
413 were amplified from ATCC 42740 and assembled into a complementation plasmid with a marker  
414 encoding hygromycin resistance (HYG) and 3' UTR using yeast recombination cloning (46). The  
415 complementation plasmid was digested with NotI and KasI resulting in a ~3500 bp fragment which was  
416 transformed into *mrs4*Δ derivatives of representative isolates along with Cas9 and a crRNA targeting the  
417 *NAT* marker.

418

419 **Analysis of *Candida auris* *MRS4* alleles.** Clade I (strain B8441), Clade II (B11220), Clade III (B11221),  
420 and Clade IV (B11245) were used in the *MRS4* sequence comparisons of *C. auris* isolates. *C. auris*



421 *MRS4* was amplified from one of two isolates from the CDC Antibiotic Resistance Isolate bank: AR bank  
422 #0382 of Clade I (Biosample Accession # SAMN18754596), and AR bank #0383 of Clade III (Biosample  
423 Accession # SAMN05379609). *C. auris MRS4* alleles were amplified using primers with 20 base pairs of  
424 overlap with *C. lusitaniae MRS4* 5' UTR and the HYG resistance cassette. *E. dermatitidis MRS4* alleles  
425 were synthesized *de novo* by Genscript with the omission of introns, and 20 base pairs of overlap with *C.*  
426 *lusitaniae MRS4* 5' UTR and the HYG resistance cassette. These sequences were then reintroduced into  
427 the native locus by complementation cassette by restriction digest, replacing the reference *MRS4* allele  
428 with the heterologous sequences. Complementation of heterologous sequences was then performed by  
429 the same method as complementation of the reference allele. Primers are listed in **Table S4**.

430  
431 **Growth Assays.** Unless otherwise stated, strains were grown as 5 ml cultures in YPD overnight (~16 h),  
432 exponential growth aliquots were washed three times and subcultured into experimental medium. For  
433 spot titer growth comparisons, cultures were diluted to 1 OD in diH<sub>2</sub>O, diluted 1:10 serially, and spotted in  
434 5 µl volumes on plates. For growth assays in 96 well plates, a starting concentration of 0.005 OD in YPD  
435 was used and stated concentrations of BPS, cobalt chloride, or cadmium chloride were added from stock  
436 solutions in water. BPS (Sigma CAS# 52746-49-3), cobalt chloride (Sigma CAS# 7791-13-1), and  
437 cadmium chloride (Sigma CAS# 654054-66-7) stocks were 100 mM, 100 mM, and 100 µM respectively.  
438 Final yield was measured by OD600 at 24 h post-inoculation. For H<sub>2</sub>O<sub>2</sub> sensitivity, fresh aliquots of 9.8 M  
439 H<sub>2</sub>O<sub>2</sub> were diluted into YPD at the time of inoculation, and growth was measured over the course of 24 h  
440 as previously described. Biolog assays were conducted by suspending 0.01 OD of each strain in YNB,  
441 and aliquoting 200µl of culture into 192 wells of two proprietary Biolog™ plates PM1 and PM2A with a  
442 diverse array of carbon sources. Growth was measured by OD600 over the course of 48 hours, and the  
443 final yield is represented in Supplementary Dataset 1.

444  
445 **TTC analysis of surface iron reductase activity.** After 24 h growth on the indicated medium, a 10 ml  
446 solution containing 0.5 mg/ml or 1 mg/ml tetrazolium chloride, 1% molten agar, and 10 mM FeCl<sub>3</sub> chloride  
447 (from 100 mM stock made fresh), if indicated, was carefully pipetted using a 10 ml serological pipette to

448 cover the entirety of the plate. Plates were incubated for the specified time (10 min to 1 h) prior to  
449 imaging.

450

451 **Transcriptome analysis of the effects *MRS4* mutation.** For RNA isolation, isolates were sub-cultured  
452 from overnight cultures into fresh YPD and grown for 6 h which corresponds to cultures in mid-  
453 exponential growth phase. Cultures were sub-cultured into six replicate 5 ml cultures of each strain which  
454 were incubated at 37C on a rollerdrum. After 5 h of growth, three replicate cultures of each strain were  
455 dosed with BPS to a final concentration of 80  $\mu$ M while the other cultures received water only. Samples  
456 were spun down in 15 ml conical tubes, snap-frozen with ethanol and dry ice, and stored for at least 1 h  
457 at -80°C. RNA extraction was performed using to MasterPure Yeast RNA Purification kit protocol  
458 (Epicentre) according to manufacturer instructions. RNA was submitted to MiGS for RNA Seq analysis.  
459 EdgeR was used for normalization and differential gene analysis of raw counts provided by MiGS. RNA-  
460 seq data have been submitted to the SRA database: #SUB10993521.

461

462 **qRT-PCR analysis.** Culture growth and RNA extraction was performed as described above for the RNA-  
463 seq analyses. RNA was DNase treated with the Turbo DNA-free Kit (Invitrogen). cDNA was synthesized  
464 from 500 ng DNase-treated RNA using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo  
465 Scientific), following the manufacturer's instructions for random hexamer primer (IDT) and GC rich  
466 template. qRT-PCR was performed on a CFX96 Real-Time System (Bio-Rad), using SsoFast Evergreen  
467 Supermix (Bio-Rad) with the primers listed in Table S4. Thermocycler conditions were as follows: 95 °C  
468 for 30 s, 40 cycles of 95 °C for 5 s, 65 °C for 3 s and 95 °C for 5 s. Transcripts were normalized to *ACT1*  
469 expression.

470

471 **Intracellular iron quantification.** Cells from overnight cultures were subcultured into YPD and grown for  
472 5 h before the addition of 80  $\mu$ M of BPS iron chelator. Samples were taken before adding chelator, and 1  
473 h after iron restriction. Samples were spun down in pre-weighed Eppendorf tubes, washed, and pellets  
474 were dried in a vacuum centrifuge for 3 h. Final dry weight was calculated for each pellet, and each was  
475 digested with 100 $\mu$ l of 70% HNO<sub>3</sub>. After overnight digestion, samples were heated to 90°C to ensure

476 complete digestion. After dilution with 3.9 ml of diH<sub>2</sub>O, samples were submitted to the Dartmouth Trace  
477 Metal Core for ICP-MS analysis of iron content.

478

479 **HPLC Supernatant Analysis.** Strains grown in overnight cultures were washed three times in dH<sub>2</sub>O and  
480 subcultured in triplicate into YNB minimal media supplemented with 100 mM glucose at a final OD of  
481 0.01. Cultures were allowed to grow for 6 hours at 37° C, then centrifuged at 13,200 RPM for 5 minutes  
482 for the separation of insoluble solids and collection of supernatant. Four blank media samples of YNB  
483 were also prepared with known concentrations of added carbon sources. One blank was supplemented  
484 with 100 mM glucose, 5 mM sodium acetate, 100 mM ethanol, 5 mM sodium citrate, 500 µM sodium  
485 lactate, 5 mM sodium succinate, 200 µM sodium pyruvate, and 100 mM glycerol, with two other blanks  
486 containing 1:10 and 1:100 dilutions of these carbon sources for the creation of a standard curve within a  
487 linear range. The final blank was prepared without any additional carbon sources. For each sample, 400  
488 µl of supernatant was centrifuged at 10,000 RPM for 2.5 minutes through Corning nonsterile nylon 0.22  
489 X-spin filters (#8169), then 20 µl of 10% sulfuric acid as added. Samples were transferred to 2 ml  
490 polypropylene snap top microvials for HPLC analysis. Samples were analyzed for levels of various sugars  
491 and organic acids utilizing a Shimadzu HPLC (LC-2030) with Biorad Aminex HPX-87H column, LC-20AD  
492 pump system, SPD-20AV detector, SIL20AC autosampler, and CTO-20AC column oven.

493

494 **Statistical Analysis.** All data were analyzed using Graph Pad Prism 8. The data represent the mean  
495 standard deviation of at least three independent experiments with three technical replicates unless stated  
496 otherwise. Comparisons were made using a two-tailed, unpaired Student's T-Test or ANOVA as  
497 indicated. One-way ANOVA tests were performed across multiple samples with Tukey's multiple  
498 comparison test for unpaired analyses.

499

#### 500 **Code availability**

501 Names of custom codes used for analysis are indicated in where appropriate in above methods.  
502 All codes and sequences are available in the indicated github repositories: analysis pipeline and scripts  
503 for whole genome genotyping and phylogeny analysis are available at

504 [https://github.com/stajichlab/PopGenomics\\_Clusitaniae](https://github.com/stajichlab/PopGenomics_Clusitaniae). These are archived with Zenodo under DOI:  
505 10.5281/zenodo.7800401. Analysis pipeline for RNA Seq data is available at [https://github.com/hoganlab-](https://github.com/hoganlab-dartmouth/Clusitaniae_DESeq2)  
506 [dartmouth/Clusitaniae\\_DESeq2](https://github.com/hoganlab-dartmouth/Clusitaniae_DESeq2) .  
507  
508

## 509 **Acknowledgements**

510 Research reported in this publication was supported by National Institutes of Health (NIH) grant R01 AI127548 to  
511 D.A.H. from the National Institute of Allergy and Infectious Diseases, T32 T32AI007519 (D.R.M). This work was  
512 supported by the Cystic Fibrosis Foundation Research Development Program (CFFRDP) STANTO19R0 for the  
513 Translational Research Core, P30-DK117469. HL122372 to A.A. from the National Heart, Lung and Blood Institute,  
514 and National Institute of General Medical Sciences (NIGMS) of the NIH under award number T32 GM008704 and  
515 AI133956 to E.G.D. J.E.S. is a CIFAR Fellow in the program Fungal Kingdom: Threats and Opportunities.

516  
517 We would like to thank Dr. Daniel Olson (Thayer School of Engineering at Dartmouth) for support for the analysis  
518 of supernatant metabolites by HPLC and Kyria Boundry-Mills who provided environmental *C. lusitaniae* strains  
519 (Phaff strain collection (UCDFST)). Intracellular iron analysis was performed by the Dartmouth Trace Element Core  
520 Facility, which was established by grants from the National Institute of Health (NIH) and National Institute of  
521 Environmental Health Sciences (NIEHS) Superfund Research Program (P42ES007373). Sequencing services were  
522 provided by the Genomics and Molecular Biology Shared Resource Core at Dartmouth (NCI Cancer Center Support  
523 Grant 5P30-CA023108). Equipment used was supported by the NIH IDeA award to Dartmouth BioMT P20-  
524 GM113132. Analyses were performed using the computational and data storage resources of the University of  
525 California-Riverside HPCC funded by grants from the National Science Foundation (NSF) (MRI-1429826) and NIH  
526 (1S10OD016290-01A1). Finally, we would like to thank the Dartmouth MCB community which provided routine  
527 feedback and provoking questions on this research.

528  
529

530 **References**

531

- 532 1. Tyrrell J, Callaghan M. 2016. Iron acquisition in the cystic fibrosis lung and potential for  
533 novel therapeutic strategies. *Microbiology (Reading)* 162:191-205.
- 534 2. Gifford AH, Moulton LA, Dorman DB, Olbina G, Westerman M, Parker HW, Stanton BA,  
535 O'Toole GA. 2012. Iron homeostasis during cystic fibrosis pulmonary exacerbation. *Clin*  
536 *Transl Sci* 5:368-73.
- 537 3. Vermilyea DM, Crocker AW, Gifford AH, Hogan DA. 2021. Calprotectin-Mediated Zinc  
538 Chelation Inhibits *Pseudomonas aeruginosa* Protease Activity in Cystic Fibrosis Sputum. *J*  
539 *Bacteriol* 203:e0010021.
- 540 4. Kim SH, Clark ST, Surendra A, Copeland JK, Wang PW, Ammar R, Collins C, Tullis DE,  
541 Nislow C, Hwang DM, Guttman DS, Cowen LE. 2015. Global Analysis of the Fungal  
542 Microbiome in Cystic Fibrosis Patients Reveals Loss of Function of the Transcriptional  
543 Repressor Nrg1 as a Mechanism of Pathogen Adaptation. *PLoS Pathog* 11:e1005308.
- 544 5. Demers EG, Biermann AR, Masonjones S, Crocker AW, Ashare A, Stajich JE, Hogan DA.  
545 2018. Evolution of drug resistance in an antifungal-naive chronic *Candida lusitaniae*  
546 infection. *Proc Natl Acad Sci U S A* 115:12040-12045.
- 547 6. Ross BS, Lofgren LA, Ashare A, Stajich JE, Cramer RA. 2021. *Aspergillus fumigatus* In-Host  
548 HOG Pathway Mutation for Cystic Fibrosis Lung Microenvironment Persistence. *mBio*  
549 12:e0215321.
- 550 7. Hogan DA, Willger SD, Dolben EL, Hampton TH, Stanton BA, Morrison HG, Sogin ML,  
551 Czum J, Ashare A. 2016. Analysis of Lung Microbiota in Bronchoalveolar Lavage,  
552 Protected Brush and Sputum Samples from Subjects with Mild-To-Moderate Cystic  
553 Fibrosis Lung Disease. *PLoS One* 11:e0149998.
- 554 8. Young LY, Hull CM, Heitman J. 2003. Disruption of ergosterol biosynthesis confers  
555 resistance to amphotericin B in *Candida lusitaniae*. *Antimicrob Agents Chemother*  
556 47:2717-24.
- 557 9. Desnos-Ollivier M, Moquet O, Chouaki T, Guerin AM, Dromer F. 2011. Development of  
558 echinocandin resistance in *Clavispora lusitaniae* during caspofungin treatment. *J Clin*  
559 *Microbiol* 49:2304-6.
- 560 10. Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. 2015. Acquired Multidrug  
561 Antifungal Resistance in *Candida lusitaniae* during Therapy. *Antimicrob Agents*  
562 *Chemother* 59:7715-22.
- 563 11. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. 2020. *Candida auris*: Epidemiology,  
564 biology, antifungal resistance, and virulence. *PLoS Pathog* 16:e1008921.
- 565 12. WHO. 2022. WHO fungal priority pathogens list to guide research, development and  
566 public health action., Geneva.
- 567 13. Zhang Y, Lyver ER, Knight SA, Pain D, Lesuisse E, Dancis A. 2006. Mrs3p, Mrs4p, and  
568 frataxin provide iron for Fe-S cluster synthesis in mitochondria. *J Biol Chem* 281:22493-  
569 502.


- 570 14. Muhlenhoff U, Stadler JA, Richhardt N, Seubert A, Eickhorst T, Schweyen RJ, Lill R,  
571 Wiesenberger G. 2003. A specific role of the yeast mitochondrial carriers MRS3/4p in  
572 mitochondrial iron acquisition under iron-limiting conditions. *J Biol Chem* 278:40612-20.
- 573 15. Li L, Kaplan J. 2004. A mitochondrial-vacuolar signaling pathway in yeast that affects iron  
574 and copper metabolism. *J Biol Chem* 279:33653-61.
- 575 16. Froschauer EM, Schweyen RJ, Wiesenberger G. 2009. The yeast mitochondrial carrier  
576 proteins Mrs3p/Mrs4p mediate iron transport across the inner mitochondrial  
577 membrane. *Biochim Biophys Acta* 1788:1044-50.
- 578 17. Foury F, Roganti T. 2002. Deletion of the mitochondrial carrier genes *MRS3* and *MRS4*  
579 suppresses mitochondrial iron accumulation in a yeast frataxin-deficient strain. *J Biol*  
580 *Chem* 277:24475-83.
- 581 18. Gupta M, Outten CE. 2020. Iron-sulfur cluster signaling: The common thread in fungal  
582 iron regulation. *Curr Opin Chem Biol* 55:189-201.
- 583 19. Xu N, Dong Y, Cheng X, Yu Q, Qian K, Mao J, Jia C, Ding X, Zhang B, Chen Y, Zhang B, Xing  
584 L, Li M. 2014. Cellular iron homeostasis mediated by the Mrs4-Ccc1-Smf3 pathway is  
585 essential for mitochondrial function, morphogenesis and virulence in *Candida albicans*.  
586 *Biochim Biophys Acta* 1843:629-39.
- 587 20. Xu N, Cheng X, Yu Q, Zhang B, Ding X, Xing L, Li M. 2012. Identification and functional  
588 characterization of mitochondrial carrier Mrs4 in *Candida albicans*. *FEMS Yeast Res*  
589 12:844-58.
- 590 21. Yates CM, Filippis I, Kelley LA, Sternberg MJ. 2014. SuSPect: enhanced prediction of  
591 single amino acid variant (SAV) phenotype using network features. *J Mol Biol* 426:2692-  
592 701.
- 593 22. Choi Y, Do E, Hu G, Caza M, Horianopoulos LC, Kronstad JW, Jung WH. 2020.  
594 Involvement of Mrs3/4 in Mitochondrial Iron Transport and Metabolism in *Cryptococcus*  
595 *neoformans*. *J Microbiol Biotechnol* 30:1142-1148.
- 596 23. Reedy JL, Floyd AM, Heitman J. 2009. Mechanistic plasticity of sexual reproduction and  
597 meiosis in the *Candida* pathogenic species complex. *Curr Biol* 19:891-9.
- 598 24. Nyhus KJ, Ozaki LS, Jacobson ES. 2002. Role of mitochondrial carrier protein Mrs3/4 in  
599 iron acquisition and oxidative stress resistance of *Cryptococcus neoformans*. *Med Mycol*  
600 40:581-91.
- 601 25. Chen C, Pande K, French SD, Tuch BB, Noble SM. 2011. An iron homeostasis regulatory  
602 circuit with reciprocal roles in *Candida albicans* commensalism and pathogenesis. *Cell*  
603 *Host Microbe* 10:118-35.
- 604 26. Skrahina V, Brock M, Hube B, Brunke S. 2017. *Candida albicans* Hap43 Domains Are  
605 Required under Iron Starvation but Not Excess. *Front Microbiol* 8:2388.
- 606 27. Weissman Z, Shemer R, Kornitzer D. 2002. Deletion of the copper transporter CaCCC2  
607 reveals two distinct pathways for iron acquisition in *Candida albicans*. *Mol Microbiol*  
608 44:1551-60.
- 609 28. Alvarez-Ortega C, Harwood CS. 2007. Responses of *Pseudomonas aeruginosa* to low  
610 oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. *Mol*  
611 *Microbiol* 65:153-165.
- 612 29. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP,  
613 Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE,




- 614 Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous  
615 Emergence of Multidrug-Resistant *Candida auris* on 3 Continents Confirmed by Whole-  
616 Genome Sequencing and Epidemiological Analyses. *Clin Infect Dis* 64:134-140.
- 617 30. Munoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, Farrer RA, Litvintseva AP,  
618 Cuomo CA. 2018. Genomic insights into multidrug-resistance, mating and virulence in  
619 *Candida auris* and related emerging species. *Nat Commun* 9:5346.
- 620 31. Kurbessoian T, Murante D, Crocker A, Hogan DA, Stajich J. 2022. In host evolution of  
621 *Exophiala dermatitidis* in cystic fibrosis lung micro-environment. *bioRxiv*  
622 2022.09.23.509114.
- 623 32. Murad AM, Leng P, Straffon M, Wishart J, Macaskill S, MacCallum D, Schnell N, Talibi D,  
624 Marechal D, Tekaiia F, d'Enfert C, Gaillardin C, Odds FC, Brown AJ. 2001. *NRG1* represses  
625 yeast-hypha morphogenesis and hypha-specific gene expression in *Candida albicans*.  
626 *Embo J* 20:4742-52.
- 627 33. Wofford JD, Lindahl PA. 2015. Mitochondrial Iron-Sulfur Cluster Activity and Cytosolic  
628 Iron Regulate Iron Traffic in *Saccharomyces cerevisiae*. *J Biol Chem* 290:26968-26977.
- 629 34. Fourie R, Kuloyo OO, Mochochoko BM, Albertyn J, Pohl CH. 2018. Iron at the Centre of  
630 *Candida albicans* Interactions. *Front Cell Infect Microbiol* 8:185.
- 631 35. Nguyen AT, O'Neill MJ, Watts AM, Robson CL, Lamont IL, Wilks A, Oglesby-Sherrouse  
632 AG. 2014. Adaptation of iron homeostasis pathways by a *Pseudomonas aeruginosa*  
633 pyoverdine mutant in the cystic fibrosis lung. *J Bacteriol* 196:2265-76.
- 634 36. Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O. 2004. Iron-source preference  
635 of *Staphylococcus aureus* infections. *Science* 305:1626-8.
- 636 37. Chen AI, Dolben EF, Okegbe C, Harty CE, Golub Y, Thao S, Ha DG, Willger SD, O'Toole GA,  
637 Harwood CS, Dietrich LE, Hogan DA. 2014. *Candida albicans* ethanol stimulates  
638 *Pseudomonas aeruginosa* WspR-controlled biofilm formation as part of a cyclic  
639 relationship involving phenazines. *PLoS Pathog* 10:e1004480.
- 640 38. Doing G, Koeppen K, Occipinti P, Harty CE, Hogan DA. 2020. Conditional antagonism in  
641 co-cultures of *Pseudomonas aeruginosa* and *Candida albicans*: An intersection of  
642 ethanol and phosphate signaling distilled from dual-seq transcriptomics. *PLoS Genet*  
643 16:e1008783.
- 644 39. Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, Rheinbay E,  
645 Grabherr M, Forche A, Reedy JL, Agrafioti I, Arnaud MB, Bates S, Brown AJ, Brunke S,  
646 Costanzo MC, Fitzpatrick DA, de Groot PW, Harris D, Hoyer LL, Hube B, Klis FM, Kodira C,  
647 Lennard N, Logue ME, Martin R, Neiman AM, Nikolaou E, Quail MA, Quinn J, Santos MC,  
648 Schmitzberger FF, Sherlock G, Shah P, Silverstein KA, Skrzypek MS, Soll D, Staggs R,  
649 Stansfield I, Stumpf MP, Sudbery PE, Srikantha T, Zeng Q, Berman J, Berriman M,  
650 Heitman J, Gow NA, Lorenz MC, Birren BW, Kellis M, et al. 2009. Evolution of  
651 pathogenicity and sexual reproduction in eight *Candida* genomes. *Nature* 459:657-62.
- 652 40. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler  
653 transform. *Bioinformatics* 25:1754-60.
- 654 41. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A,  
655 Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altschuler D, Gabriel S,  
656 DePristo MA. 2013. From FastQ data to high confidence variant calls: the Genome  
657 Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* 43:11 10 1-11 10 33.




- 658 42. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM.  
659 2012. A program for annotating and predicting the effects of single nucleotide  
660 polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118;  
661 iso-2; iso-3. *Fly (Austin)* 6:80-92.
- 662 43. Schubert M, Lindgreen S, Orlando L. 2016. AdapterRemoval v2: rapid adapter trimming,  
663 identification, and read merging. *BMC Res Notes* 9:88.
- 664 44. N. Joshi JF. 2011. Sickle: A sliding-window, adaptive, quality-based trimming tool for  
665 FastQ files (Version 1.33), Available at <https://github.com/najoshi/sickle>.
- 666 45. Grahl N, Demers EG, Crocker AW, Hogan DA. 2017. Use of RNA-Protein Complexes for  
667 Genome Editing in Non-albicans *Candida* Species. *mSphere* 2.
- 668 46. Shanks RM, Caiazza NC, Hinsa SM, Toutain CM, O'Toole GA. 2006. *Saccharomyces*  
669 *cerevisiae*-based molecular tool kit for manipulation of genes from gram-negative  
670 bacteria. *Appl Environ Microbiol* 72:5027-36.  
671




**Figure 1. Non-synonymous SNPs in *MRS4* were found in whole genome sequence data from 12-20 *C. lusitaniae* isolates from each of three subjects with chronic CF infections. A)** Analysis of loci that were heterogeneous in three *C. lusitaniae* populations in three separate individuals (Subjects A, B, and C) found that only *CLUG\_02526 (MRS4)* had subpopulations with non-synonymous substitutions in all three infections. **B)** Two *MRS4* alleles were detected in each population. “REF” indicates the *MRS4* sequence in environmental and acute infection isolates of *C. lusitaniae*. **C)** The *MRS4* sequence encodes a barrel-structure iron transporter on the inner mitochondrial membrane; the protein is 318 amino acids long and comprised of six transmembrane alpha-helices denoted by light blue bars. Each mutation is predicted to disrupt or truncate one of these transmembrane domains (see SUSPECT analysis, Fig S3). **D)** Pooled sequencing was performed on isolates from bronchoalveolar lavage fluid taken from specific lobes of subjects A and B. The relative abundances of *MRS4* alleles was quantified by analysis of individual reads.




**Figure 2.** *Mrs4*<sup>Q254\*</sup> confers loss of function in *C. lusitaniae*. **A)** An *mrs4*Δ mutant and *mrs4*Δ mutants complemented with *MRS4*<sup>Q254\*</sup> or the *MRS4*<sup>REF</sup> were constructed in the B\_L01 clinical isolate background **B)** Strains were assessed for growth in a 96-well plate after 24 h at 37° in YPD or YPD with 80 μM BPS iron chelator. Columns labelled with *a* are non-significantly different from each other, and are significantly different from columns labelled with *b* and *c*. **C)** Indicated strains were grown for 24 h at 37° in YPD supplemented with 2.5 mM CoCl<sub>2</sub> (left) and 12.5 μM CdCl<sub>2</sub> (right). There were at least three replicates per sample. Indicated p-values are from a one-way ANOVA with Tukey's post-hoc correction, ns, not significant.




**Figure 3. *MRS4* mutations in each clinical population demonstrate LOF phenotypes.** Representative parent isolates of each mutation from Subject B (B\_L04, *MRS4*<sup>A147D</sup>), Subject A (A\_U05, *MRS4*<sup>A235V</sup>), and Subject C, (C\_M06, *MRS4*<sup>G138V</sup>) and their *mrs4*Δ derivatives that were then complemented with the *MRS4*<sup>REF</sup> allele, were grown in YPD supplemented with **A)** 2.5 mM CoCl<sub>3</sub> and **B)** 12.5 μM CdCl<sub>2</sub>. Data represent the endpoint OD600 measured by a Synergy Neo2 plate reader after 24 h of growth at 37°. Indicated p-values are from one-way ANOVA with Tukey's post-hoc, ns, not significant.




**Figure 4. Lack of MRS4 growth phenotypes in complex and minimal media with glycerol and glucose.** Cells from exponential phase cultures of B\_L01, its *mrs4*Δ derivative, and *mrs4*Δ mutants complemented with *MRS4*<sup>Q254\*</sup> or the *MRS4*<sup>REF</sup> were inoculated into a 96-well plate and grown for 24 h at 37° in YP medium supplemented with **A)** 2% glucose or **B)** 2% glycerol or in YNB defined medium without amino acids supplemented with **C)** 2% glucose or **D)** 2% glycerol. OD<sub>600</sub> was measured over time using a Synergy Neo2 plate reader.



**Figure 5. Loss of *Mrs4* function leads to increased expression of iron acquisition genes.** **A)** Design of RNA-seq sample preparation. Sextuplicate cultures of B\_L01 *mrs4* $\Delta$  complemented with either *REF* or *Q254\** *MRS4* alleles were grown overnight, then sub-cultured into YPD and grown for 5 h. Cultures were grown for an additional hour with either 80 $\mu$ M BPS or vehicle prior to RNA isolation. Gene expression heatmaps of differentially expressed genes (P < 0.05 and a log<sub>2</sub> fold-change  $\geq$  |1|) in a comparison between **B)** the B\_L01::*MRS4*<sup>REF</sup> strain grown in YPD (iron replete) or YPD with BPS (iron deplete) **C)** B\_L01::*MRS4*<sup>REF</sup> and B\_L01::*MRS4*<sup>Q254\*</sup> grown in YPD with BPS, and **D)** B\_L01::*MRS4*<sup>REF</sup> and B\_L01::*MRS4*<sup>Q254\*</sup> grown in YPD.



**Figure 6. Decreased *Mrs4* function increases ferric reductase activity and intracellular iron content.** **A)** B\_L01 derived strains *mrs4*Δ, *mrs4*Δ::*MRS4*<sup>REF</sup>, *mrs4*Δ::*MRS4*<sup>Q254\*</sup> were spotted on YNB-glycerol plates. Plates were incubated for 24 h at 37°C. Each plate was overlaid with a 10 ml solution of 1 mg/ml tetrazolium chloride (TTC) and incubated for 5 min prior to imaging. Red pigmentation indicates greater levels of ferric iron reduction. Inclusion of 10 mM of FeCl<sub>3</sub> (+Fe) as a competitor eliminates TTC reduction. **B)** B\_L01 derived strains *mrs4*Δ, *mrs4*Δ::*MRS4*<sup>REF</sup>, *mrs4*Δ::*MRS4*<sup>Q254\*</sup> and *hap43*Δ were serially diluted from 1 OD and spotted on YPD plates, then allowed to grow for 24 hours at 37°C then analyzed as in panel A. **C)** *C. lusitaniae* DH2383 and its *mrs4*Δ mutant and *C. albicans* SC5314 with single and double knockouts of *mrs4* were analyzed for surface ferric reductase activity on YNB-glycerol. **D)** B\_L01 *mrs4*Δ strains complemented with *MRS4*<sup>REF</sup> and *MRS4*<sup>Q254\*</sup> alleles were grown in YPD or YPD + 80 μM BPS as outlined in Fig. 5A. Whole cell iron was quantified using ICP-MS. Data represents the averages of three technical replicates for two experiments done on separate days. Indicated p-values are from Student's t-tests.



**Figure 7. An *Mrs4* loss-of-function subpopulation also emerged in *Exophiala dermatitidis* during a chronic CF lung infection. A)** Two alleles of *MRS4* were found in *E. dermatitidis* isolates from in a single chronic CF lung infection. Of the 23 isolates sequenced, seven genomes encoded the reference *Mrs4*<sup>40E</sup> (*E.d. REF*), which is identical to previously sequenced *E. dermatitidis* strains, and sixteen isolates encoded an *Mrs4*<sup>40G</sup> variant (*E40G*). **B)** *C. lusitaniae* B\_L01 *mrs4Δ* strains complemented with the two *E. dermatitidis* *MRS4* alleles grown in YPD with 80 μM BPS for 24 h. *C. lusitaniae* B\_L01 *mrs4Δ* expressing functional *MRS4*<sup>REF</sup> or *MRS4*<sup>Q254\*</sup> were included for comparison. Indicated p-value are from a one-way ANOVA with Tukey's post-hoc, ns, not significant.